Tango Therapeutics, Inc. (TNGX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jessica Newcomb

Principal Accounting Officer

—

$157.66K (2) scheduled

−$157.66K

52,090

0.0309%

$1.20M

−22.6%

Adam Crystal

President, R&D

—

$112.11K (2) scheduled

−$112.11K

115,743

0.0686%

$2.66M

−5.6%

Third Rock Ventures IV, L.P. entity

10% owner

—

13,386,574

7.94%

$307.64M

−20.6%

EcoR1 Capital, LLC entity

10% owner

—

10,630,736

6.30%

$244.31M

−20.3%

Boxer Capital Management, LLC entity

See remarks

—

3,610,642

2.14%

$82.98M

−46.0%

Barbara Weber

Director, Executive Chair

—

1,629,254

0.9663%

$37.44M

+6.1%

Malte Peters

President & CEO

—

367,500

0.2180%

$8.45M

+3,167%

Daniella Beckman

Chief Financial Officer

—

184,297

0.1093%

$4.24M

+39.2%

Douglas Barry

General Counsel

—

66,014

0.0392%

$1.52M

+50.1%

Mace Rothenberg

Director

—

41,500

0.0246%

$953.74K

+268.9%

Matthew Gall

Chief Financial Officer

—

40,000

0.0237%

$919.26K

—

John B Ketchum

Director

—

24,937

0.0148%

$573.09K

+69.8%

Sung Lee

Director

—

22,870

0.0136%

$525.59K

—

Alexis Borisy

Director

—

17,500

0.0104%

$402.18K

+55.6%

Lesley Ann Calhoun

Director

—

16,500

0.0098%

$379.20K

+164.0%

Robert Azelby

Director

—

5,740

0.0034%

$131.91K

—

Tango Therapeutics, Inc.

What the insiders did Scheduled selling only

By person